Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: Abrogation by a new inhibitor of glucosylceramide synthase

Journal of Neurochemistry

Volumn 70, Issue 2, 1998, Pages 467-472

  Olshefski, Randal ^a,b   Ladisch, Stephan ^a,b,c  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Ganglioside shedding; Ganglioside transfer; Glucosylceramide synthase inhibition; Medulloblastoma

Indexed keywords

1 PHENYL 2 HEXADECANOYLAMINO 3 PYRROLIDINO 1 PROPANOL; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; GANGLIOSIDE; GLUCOSYLCERAMIDE; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; LIPID TRANSPORT; LIPOGENESIS; MEDULLOBLASTOMA; PRIORITY JOURNAL;

EID: 0031887067     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70020467.x     Document Type: Article

References (38)

1. Abe A., Radin N., Shayman J., Wotring L., Zipkin R., Sivakumar R., Ruggieri J., Carson K., and Ganem B. (1995) Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36, 611-621.
2. Alessandri G., Filippeschi S., Sinibaldi P., Mornet F., Passera P., Spreafico F., Cappa P. M., and Gullino P. M. (1987) Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 47, 4243-4247.
3. Bernhard H., Meyer zum Buschenfelde K. H., and Dippold W. G. (1989) Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer 44, 155-160.
4. Black P. H. (1980) Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res. 32, 75-199.
5. Chang F., Li R., and Ladisch S. (1997a) Shedding of human medulloblastoma gangliosides. Exp. Cell Res. 234, 341-346.
6. Chang F., Li R., Noon K., Gage D., and Ladisch S. (1997b) Human medulloblastoma gangliosides. Glycobiology 7, 523-530.
7. Chu J. W. K. and Sharom F. J. (1993) Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 79, 10-17.
8. Facci L., Leon A., Toffano G., Sonnino S., Ghidoni R., and Tettamanti G. (1984) Promotion of neuritogenesis in mouse neuroblastoma cells by exogenous gangliosides. Relationship between the effect and the cell association of ganglioside GM1. J. Neurochem. 42, 299-305.
9. Grayson G. and Ladisch S. (1992) Immunosuppression by human gangliosides. II. Carbohydrate structure and the inhibition of natural cytotoxicity. Cell. Immunol. 139, 18-29.
10. Heideman R., Packer R., Albright L., Freeman C., and Rouke L. (1997) Tumors of the central nervous system, in Principles and Practice of Pediatric Oncology (Pizzo P. and Poplack D., eds), pp. 633-697. Lippincott-Raven, Philadelphia.
11. Heitger A. and Ladisch S. (1996) Gangliosides block antigen presentation by human monocytes. Biochim. Biophys. Acta 1303, 161-168.
12. Jacobsen P. F., Jenkyn D. J., and Papadimitriou J. M. (1985) Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J. Neuropathol. Exp. Neurol. 44, 472-485.
13. Kemp S. F. and Stoolmiller A. C. (1976) Biosynthesis of glycosphingolipids in cultured mouse neuroblastoma cells. J. Biol. Chem. 251, 7626-7631.
14. Koochekpour S. and Pilkington G. J. (1996) Vascular and perivascular GD3 expression in human glioma. Cancer Leu. 104, 97-102.
15. Ladisch S. and Gillard B. (1985) A solvent partition method for microscale ganglioside purification. Anal. Biochem. 146, 220-231.
16. Ladisch S. and Wu Z.-L. (1985) Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. Lancet i, 136-138.
17. Ladisch S., Gillard B., Wong C., and Ulsh L. (1983) Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43, 3808-3813.
18. Ladisch S., Ulsh L., Gillard B., and Wong C. (1984) Modulation of the immune response by gangliosides: inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 74, 2074-2081.
19. Ladisch S., Wu Z.-L., Feig S., Ulsh L., Schwartz E., Floutsis G., Wiley F., Lenarsky C., and Seeger R. (1987a) Shedding of GD2 ganglioside by human neuroblastoma. Int. J. Cancer 39, 73-76.
20. Ladisch S., Kitada S., and Hays E. (1987b) Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Invest. 79, 1879-1882.
21. Ladisch S., Becker H., and Ulsh L. (1992) Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta 1125, 180-188.
22. Ladisch S., Chang F., Li R., Cogen P., and Johnson D. (1997) Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett. 118, 1-7.
23. Ledeen R. and Yu R. (1982) Gangliosides: structures, isolation and analysis. Methods Enzymol. 83, 139-191.
24. Lengle E. E., Krishnaraj R., and Kemp R. G. (1979) Inhibition of the lectin-induced mitogenic response of thymocytes by glycolipids. Cancer Res. 39, 817-822.
25. Li R. and Ladisch S. (1991) Shedding of human neuroblastoma gangliosides. Biochim. Biophys. Acta 1083, 57-64.
26. Li R. and Ladisch S. (1996) Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res. 56, 4602-4605.
27. Li R., Gage D., and Ladisch S. (1993) Biosynthesis and shedding of murine lymphoma gangliosides. Biochim. Biophys. Acta 1170, 283-290.
28. Li R., Villacreses N., and Ladisch S. (1995) Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res. 55, 211-214.
29. Lu P. and Sharom F. J. (1996) Immunosuppression by YAC-1 lymphoma: role of shed gangliosides. Cell. Immunol. 173, 22-32.
30. Markwell M. A., Haas S. M.,Tolbert N. E., and Bieber L. L. (1981) Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol. 72, 296-303.
31. Olshefski R. and Ladisch S. (1996) Intracellular transfer of shed tumor cell gangliosides. FEBS Lett. 386, 11-14.
32. Portoukalian J., David M.-J., Gain P., and Richard M. (1993) Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53, 948-951.
33. Saha S. and Chattopadhyay U. (1988) Changes in plasma gangliosides in relation to tumor growth and their tumor-enhancing effect. Int. J. Cancer 41, 432-435.
34. Saqr H. E., Pearl D. K., and Yates A. J. (1993) A review and predictive models of ganglioside uptake by biological membranes. J. Neurochem. 61, 395-411.
35. Schulz G., Cheresh D., Varki N., Yu A., Staffileno L., and Reisfeld R. (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44, 5914-5920.
36. Shaposhnikova G. I., Prokazova N. V., Buznikov G. A., Zvezdina N. D., Teplitz N. A., and Bergelson L. D. (1984) Shedding of gangliosides from tumor cells depends on cell density. Eur. J. Biochem. 140, 567-570.
37. Valentino L., Moss T., Olson E., Wang H.-J., Elashoff R., and Ladisch S. (1990) Shed tumor gangliosides and progression of human neuroblastoma. Blood 75, 1564-1567.
38. Whisler R. and Yates A. (1980) Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation. J. Immunol. 125, 2106-2111.